BMS-229724

BMS-229724 is an orally active and tight-binding cytosolic phospholipase A2 (cPLA2) inhibitor with an IC50 of 2.8 μM. BMS-229724 can inhibit the production of arachidonic acid and eicosanoids in U937 cells, neutrophils, platelets, and other cells. BMS-229724 has anti-inflammatory activity and can be used in the research of diseases such as skin inflammation[1][2].

Product Specifications

CAS Number

[221914-85-8]

UNSPSC

12352005

Target

Phospholipase

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Smiles

O=C(CCC1=CC=C(OCCS(=O)(CCOC(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)=O)C=C1)C(F)(F)F

Molecular Formula

C27H25Cl2F3O5S

Molecular Weight

589.45

References & Citations

[1]Magrioti V, et al. Synthetic inhibitors of group IVA and group VIA phospholipase A2[J]. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistryrrent Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents), 2006, 5 (2) : 189-203.|[2]Burke JR, et al. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J Pharmacol Exp Ther. 2001 Jul;298 (1) :376-85.